Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: An observational study

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 24, Issue 9, 2014, Pages 1035-1042

  Rossi, M ^a,b,c   Campbell, K ^a,b,c   Johnson, D ^a,b,c   Stanton, T ^a,c   Pascoe, E ^a   Hawley, C ^a,c   Dimeski, G ^a,c   McWhinney, B ^d   Ungerer, J ^d   Isbel, N ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Cardiovascular disease; Chronic kidney disease; Indoxyl sulphate; P Cresyl sulphate; Uraemic toxins

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN; INDICAN; LOW DENSITY LIPOPROTEIN; P CRESYL SULPHATE; PHOSPHATE; SULFATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREMIC TOXIN; 4-CRESOL SULFATE; BIOLOGICAL MARKER; CRESOL;

ADULT; ANTHROPOMETRY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BINDING; SMOKING; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; AGED; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; BLOOD; BRACHIAL ARTERY; CHRONIC KIDNEY FAILURE; FOLLOW UP; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

AGED; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CRESOLS; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDICAN; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; SULFURIC ACID ESTERS; VASCULAR STIFFNESS;

EID: 84929047513     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.04.006     Document Type: Article

References (31)

1. El Nahas A.M., Bello A.K. Chronic kidney disease: the global challenge. Lancet 2005, 365(9456):331-340.
2. Rossi M., Campbell K.L., Johnson D.W. Indoxyl sulphate and p-cresyl sulphate: therapeutically modifiable nephrovascular toxins. OA Nephrol 2013, 1(2):13.
3. Dou L., Bertrand E., Cerini C., Faure V., Sampol J., Vanholder R., et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004, 65(2):442-451.
4. Motojima M., Hosokawa A., Yamato H., Muraki T., Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003, 63(5):1671-1680.
5. Watanabe H., Miyamoto Y., Honda D., Tanaka H., Wu Q., Endo M., et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int 2013, 83(4):582-592.
6. Sun C.Y., Chang S.C., Wu M.S. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One 2012, 7(3):e34026.
7. Barreto F.C., Barreto D.V., Liabeuf S., Meert N., Glorieux G., Temmar M., et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009, 4(10):1551-1558.
8. Wu I.W., Hsu K.H., Lee C.C., Sun C.Y., Hsu H.J., Tsai C.J., et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2010, 26(3):938-947.
9. Wu I.W., Hsu K.H., Hsu H.J., Lee C.C., Sun C.Y., Tsai C.J., et al. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients-a prospective cohort study. Nephrol Dial Transplant 2012, 27(3):1169-1175.
10. Lin C.J., Liu H.L., Pan C.F., Chuang C.K., Jayakumar T., Wang T.J., et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res 2012, 43(6):451-456.
11. Owada A., Nakao M., Koike J., Ujiie K., Tomita K., Shiigai T. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl 1997, 63:S188-S190.
12. Yu M., Kim Y.J., Kang D.H. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011, 6(1):30-39.
13. Smith E.A., Macfarlane G.T. Formation of phenolic and indolic compounds by anaerobic bacteria in the human large intestine. Microb Ecol 1997, 33(3):180-188.
14. Vaziri N.D., Wong J., Pahl M., Piceno Y.M., Yuan J., DeSantis T.Z., et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013, 83(2):308-315.
15. Poesen R., Viaene L., Verbeke K., Claes K., Bammens B., Sprangers B., et al. Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J Am Soc Nephrol 2013, 8(9):1508-1514.
16. Lin C.J., Chen H.H., Pan C.F., Chuang C.K., Wang T.J., Sun F.J., et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 2011, 25(3):191-197.
17. Melamed M.L., Plantinga L., Shafi T., Parekh R., Meyer T.W., Hostetter T.H., et al. Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators. BMC Nephrol 2013, 14(1):134.
18. Schulman G, Berl T, Beck GJ, remuzzi G, Ritz E, Univ V. EPPIC (Evaluating Prevention of Progression in Chronic Kidney Disease): results from 2 phase III, randomized, placebo-controlled, double-blind trials of AST-120 in Adults with CKD ASN 2012; A: PO1106.
19. Isbel N.M., Haluska B., Johnson D.W., Beller E., Hawley C., Marwick T.H. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J 2006, 151(3):745-753.
20. KDIGO KDIGO 2012 clinial practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int 2013, 3(1).
21. Pretorius C.J., McWhinney B.C., Sipinkoski B., Johnson L.A., Rossi M., Campbell K.L., et al. Reference ranges and biological variation of free and total serum indoxyl- and p-cresyl sulphate measured with a rapid UPLC fluorescence detection method. Clin Chim Acta 2013, 419:122-126.
22. Petchey W.G., Hawley C.M., Johnson D.W., Haluska B.A., Watkins T.W., Isbel N.M. Multimodality vascular imaging in CKD: divergence of risk between measured parameters. Nephrol Dial Transplant: Off Pub Eur Dial Transplant Assoc - Eur Renal Assoc 2012, 27(3):1004-1012.
23. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.Y., Keilbaugh S.A., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334(6052):105-108.
24. Niwa T., Nomura T., Sugiyama S., Miyazaki T., Tsukushi S., Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 1997, 62:S23-S28.
25. Schulman G., Agarwal R., Acharya M., Berl T., Blumenthal S., Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006, 47(4):565-577.
26. Liabeuf S., Barreto D.V., Barreto F.C., Meert N., Glorieux G., Schepers E., et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010, 25(4):1183-1191.
27. Watanabe H., Noguchi T., Miyamoto Y., Kadowaki D., Kotani S., Nakajima M., et al. Interaction between two sulfate conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate, during binding with human serum albumin. Drug Metab Dispos 2012, 40(7):1423-1428.
28. Moradi H., Sica D.A., Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol 2013, 38(2):136-148.
29. Shimazu S., Hirashiki A., Okumura T., Yamada T., Okamoto R., Shinoda N., et al. Association between indoxyl sulfate and cardiac dysfunction and prognosis in patients with dilated cardiomyopathy. Circ J 2013, 77(2):390-396.
30. Hsu C.C., Lu Y.C., Chiu C.A., Yu T.H., Hung W.C., Wang C.P., et al. Levels of indoxyl sulfate are associated with severity of coronary atherosclerosis. Clin Invest Med 2013, 36(1):E42-E49.
31. Sato B., Yoshikawa D., Ishii H., Kikuchi R., Arima T., Takeshita K., et al. Indoxyl sulfate, a uremic toxin, and carotid intima-media thickness in patients with coronary artery disease. Int J Cardiol 2013, 163(2):214-216.